Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Bump Coming??
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(599)
•••
Comment by davewhoon Aug 12, 2021 1:56pm
160 Views
Post# 33694929

RE:Bump Coming??

RE:Bump Coming??WELL getting that bump today. We wait for our turn.

Aug 12 (Reuters) - WELL Health Technologies Corp:

* WELL HEALTH ACHIEVES RECORD REVENUE AND ADJUSTED EBITDA IN Q2-2021; WITH 484% YOY REVENUE GROWTH; AND 615% GROWTH IN ITS ADJUSTED GROSS PROFIT

* ON TRACK TO ACHIEVE ITS GOALS FOR 2021

* EXPECTING ITS SUBSTANTIAL REVENUE AND EBITDA GROWTH EXPERIENCED IN Q2 WILL CONTINUE INTO Q3

* QTRLY NET LOSS PER SHARE $0.08

* QTRLY REVENUE $61.8 MILLION VERSUS $10.6 MILLION

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities